Advertisement

Topics

Latest "Mifepristone Cushing Syndrome" News Stories

01:00 EDT 30th April 2017 | BioPortfolio

Here are the most relevant search results for "Mifepristone Cushing Syndrome" found in our extensive news archives from over 250 global news sources.

More Information about Mifepristone Cushing Syndrome on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Mifepristone Cushing Syndrome for you to read. Along with our medical data and news we also list Mifepristone Cushing Syndrome Clinical Trials, which are updated daily. BioPortfolio also has a large database of Mifepristone Cushing Syndrome Companies for you to search.

Showing "Mifepristone Cushing Syndrome" News Articles 1–25 of 2,200+

Extremely Relevant

Hair analysis may help diagnose Cushing Syndrome

Analyzing a hair sample may help with the diagnosis of Cushing Syndrome, a rare and potentially fatal disorder in which the body overproduces the stress hormone cortisol, according to researchers at the National Institutes of ... Read more


Hair Sample Might Aid in Cushing's Syndrome Diagnosis

A 1-cm hair sample closest to the scalp was found to be a potential marker for hypercortisolemia in patients suspected of having Cushing's syndrome. Medscape Medical News

Hair analysis may help diagnose Cushing syndrome, researchers report

Analyzing a hair sample may help with the diagnosis of Cushing Syndrome, a rare and potentially fatal disorder in which the body overproduces the stress hormone cortisol, according to researchers at the National Institutes of Health.


Medical News Today: Cushing's syndrome: Could analyzing hair confirm diagnosis?

Researchers from the National Institutes of Health find that cortisol levels detected in hair might be able to confirm a diagnosis of Cushing's syndrome.

Iatrogenic cushing's syndrome described in 9-year-old girl

(HealthDay)—In a case report published online Jan. 19 in Pediatrics, iatrogenic Cushing's syndrome (CS) is described in a 9-year-old girl who received topical ocular glucocorticoid (GC) treatment for bilateral iridocyclitis.

Relevant

Millendo Therapeutics Announces Initiation Of Phase II Clinical Trial Of ATR-101 In Patients With Endogenous Cushing???s Syndrome

  Life Sciences Jobs   ...

Hair Test for Cushing Syndrome?

(MedPage Today) -- Cortisol levels in hair correlated strongly with standard tests

Revised Commentary on Corcept's S-3 Registration - After Talking to Management

When we originally released our latest post on Corcept Therapeutics (CORT), we had not yet spoken to management.Explanation for S-3The recent S-3 filing for registering shares is a “just in case”. It is for raising money in the case an unexpected event. For example, if a clinical trial returns surprisingly good results, Corcept management may feel compelled to initiate a large clinical trial. ...

Hair analysis may help diagnose Cushing Syndrome, NIH researchers report

Small study suggests that high cortisol level in hair may foretell hard-to-diagnose disorder.

Why is Corcept Raising Capital? REVISED

When we originally released this post, we had not yet spoken to management. The recent S-3 filing for registering shares is a “just in case”. The older S-3 is expiring. The new S-3 covers unexpected program changes (e.g. surprisingly good results in a major indication). FO Charlie Robb confirmed what he stated in the latest conference call: As we have said in past calls, we believe revenu...

Is Corcept's Cushing's Program Going to Die?

On Tuesday December 20, 2016, Corcept Therapeutics (CORT) opened at $8.47 and then quickly fell to $7.80 before ending at $8.33.  Investment Bank Janney Montgomery Scott initiated coverage on Corcept with a sell rating and $7.00 price objective. The quick fall was attributed to selling int he wake of the report.Among other things, it reportedly raised objections to the expiring protection for...

Millendo commences Phase II trial of ATR-101 to treat endogenous CS

US-based biopharmaceutical firm Millendo Therapeutics has commenced a Phase II clinical trial of ATR-101 for the treatment of patients with endogenous cushing’s syndrome (CS).

Corcept Therapeutics: How is the Cushing's Program Protected?

On Tuesday December 20, 2016, Corcept Therapeutics (CORT) opened at $8.47 and then quickly fell to $7.80 before ending at $8.33.  Investment Bank Janney Montgomery Scott initiated coverage on Corcept with a sell rating and $7.00 price objective. The quick fall was attributed to selling int he wake of the report.Among other things, it reportedly raised objections to the expiring protection for...

Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing’s Syndrome

Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases caused by hormone dysregulation, today announced the initiation of a Phase 2 clinical trial evaluating the safety and efficacy of a novel oral drug

Why is Corcept Raising Capital?

As of the morning of March 14, 2017, the Nasdaq is down and also Corcept Therapeutics (CORT). Although there may be some profit taking, CORT’s dip may also be a reaction to the recent filing of its registration statement. As we have mentioned before, there are some investors who are interested in Corcept as an earnings story. Although Corcept derives sales revenues from a single indication, we t...

Corcept Therapeutics Announces Encouraging Results of Phase 1/2 Trial of Mifepristone Plus Eribulin in Triple-Negative Breast Cancer

MENLO PARK, CA -- (Marketwired) -- 12/10/16 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, psychiatric and oncologic disorders by modulating the effects of the stress hormone cortisol, released efficacy data today from its Phase 1/2 trial of mifepristone to treat patien...

Cortisol excess hits natural DNA process and mental health hard

High concentrations of the stress hormone cortisol affect important DNA processes and increase the risk of long-term psychological consequences. These relationships are evident in a study from the Sahlgrenska Academy on patients with Cushing's syndrome, but the findings also open the door for new treatment strategies for other stress-related conditions such as anxiety, depression and post-traumati...

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results; Increases 2017 Revenue Guidance

MENLO PARK, CA -- (Marketwired) -- 03/06/17 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today reported financial results for the quarter- and ...

Brief Roundup Part II - Conatus (CNAT) and Corcept (CORT)

In Part 1, we wrote our brief thoughts about BioMarin (BMRN) and Capricor (CAPR). Part 2 is focused on Conatus (CNAT) and Corcept (CORT). Conatus Pharmaceutical (CNAT)Conatus recently announced a collaboration

Corcept Therapeutics Announces Preliminary Fourth Quarter and Full-Year 2016 Financial Results and Corporate Update; Provides 2017 Revenue Guidance

MENLO PARK, CA -- (Marketwired) -- 01/30/17 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today reported preliminary financial results for the q...

STRESS : L'excès de cortisol chahute notre ADN - Scientific Reports

Des concentrations élevées de l'hormone du stress, le cortisol, dans le corps affectent des processus clés de l'ADN et augmentent le risque de conséquences psychologiques à long terme. Cette étude de l'Université de Göteborg menée auprès de patients atteints du syndrome de Cushing (associé à une surproduction substan...

[Seminar] Haemolytic uraemic syndrome

Haemolytic uraemic syndrome is a form of thrombotic microangiopathy affecting predominantly the kidney and characterised by a triad of thrombocytopenia, mechanical haemolytic anaemia, and acute kidney injury. The term encompasses several disorders: shiga toxin-induced and pneumococcus-induced haemolytic uraemic syndrome, haemolytic uraemic syndrome associated with complement dysregulation or mutat...

A new immunologic and endocrine syndrome

The name of the gene is Armc5, for Armadillo repeat containing 5. Until now, its function was unknown. After 10 years of research, a team at the University of Montreal Hospital Research Centre (CRCHUM) has succeeded in deleting this gene in experimental mice and discovered that its loss gives rise to a heretofore unidentified syndrome. This syndrome is provisionally called Armadillo Syndrome.

Modified Atkins Diet helps children suffering from Doose syndrome

Doose syndrome or myoclonic-astatic epilepsy is a rare syndrome accounting for one to two percent of childhood epilepsies.

Corcept Therapeutics Inc. Announces Encouraging Results Of Phase 1/2 Trial Of Mifepristone Plus Eribulin In Triple-Negative Breast Cancer

  Life Sciences Jobs   ...


Quick Search
Advertisement
 

News Quicklinks